"Extension at 10 Years of the: Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

March 16, 2017

Study Completion Date

June 21, 2018

Conditions

Hemophilia A

Interventions

DRUG

Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Administered 20-30 IU/kg 3 times a week

DRUG

Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Administered only for bleeding episodes

Trial Locations (1)

Multiple Locations